Dr. Evans on the Tolerability of CDK4/6 Inhibitors in HR+ Breast Cancer
November 9th 2018
Terry L. Evans, MD, clinical assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the tolerability of CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.